Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials,...

Descripción completa

Detalles Bibliográficos
Autores principales: Funakoshi, Yusuke, Hata, Nobuhiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Fujioka, Yutaka, Takigawa, Kosuke, Mizoguchi, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766528/
https://www.ncbi.nlm.nih.gov/pubmed/33339404
http://dx.doi.org/10.3390/ph13120470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766528/
https://www.ncbi.nlm.nih.gov/pubmed/33339404
http://dx.doi.org/10.3390/ph13120470

Ejemplares similares